<DOC>
	<DOCNO>NCT02166476</DOCNO>
	<brief_summary>Carbavance , ( meropenem/vaborbactam ) compare piperacillin/tazobactam treatment adult cUTIs AP</brief_summary>
	<brief_title>Efficacy , Safety , Tolerability Carbavance Compared Piperacillin/Tazobactam Complicated Urinary Tract Infections ( cUTIs ) , Including Acute Pyelonephritis ( AP ) , Adults</brief_title>
	<detailed_description>In current era increase resistance extend spectrum cephalosporin , carbapenem antimicrobial agent frequently antibiotics `` last defense '' resistant pathogens serious infection , include find cUTIs . The recent dissemination serine carbapenemases Enterobacteriaceae many hospital worldwide pose considerable threat carbapenems member beta-lactam class antimicrobial agent . Rempex develop Carbavance ( meropenem/vaborbactam ) administer fix combination intravenous ( IV ) infusion , treat serious Gram-negative infection , cUTIs , include infection cause bacteria resistant currently available carbapenems .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Urinary Tract Infections</mesh_term>
	<mesh_term>Pyelonephritis</mesh_term>
	<mesh_term>Meropenem</mesh_term>
	<mesh_term>Tazobactam</mesh_term>
	<mesh_term>Penicillanic Acid</mesh_term>
	<mesh_term>Piperacillin</mesh_term>
	<mesh_term>Levofloxacin</mesh_term>
	<mesh_term>Ofloxacin</mesh_term>
	<mesh_term>Piperacillin , tazobactam drug combination</mesh_term>
	<mesh_term>beta-Lactamase Inhibitors</mesh_term>
	<criteria>1 . A sign informed consent form , ability understand study conduct task require study participation , willingness cooperate task , test , examination require protocol . 2 . Male female ≥18 year age . 3 . Weight ≤185 kilogram ( kg ) . 4 . Expectation , judgment Investigator , participant 's cUTI AP require initial treatment least 5 day IV antibiotic . 5 . Documented suspected cUTI AP define : cUTI Signs symptom evidence least 2 follow : Chills , rigor , fever ( fever must document within 24 hour screen visit , temperature ≥38.0°C [ ≥100.4°F ] rectal/core temperature ≥38.3°C [ ≥100.9°F ] , observe document health care provider ) ; Elevated white blood cell count ( &gt; 10,000/ cubic millimeter [ mm^3 ] ) leave shift ( &gt; 15 % immature polymorphonuclear leukocytes [ PMNs ] ) ; Nausea vomiting ; Dysuria , increase urinary frequency , urinary urgency ; Lower abdominal pain pelvic pain Pyuria evidence 1 following : Positive leukocyte esterase ( LCE ) urinalysis ; White blood cell count ≥10 cells/mm^3 unspun urine ; White blood cell count ≥10 cells/highpower field ( hpf ) urine sediment At least 1 follow associate risk : Indwelling urinary catheter ; Neurogenic bladder presence history urine residual volume ≥100 mL ; Obstructive uropathy ( , nephrolithiasis , tumor , fibrosis ) expect medically surgically treat within 48 hour post randomization ; Azotemia due intrinsic renal disease ; Urinary retention men due previously diagnose benign prostatic hypertrophy AP Signs symptom evidence least 2 follow : Chills , rigor , fever ( Fever must document within 24 hour screen visit , temperature ≥38.0°C [ ≥100.4°F ] rectal/core temperature ≥38.3°C [ ≥100.9°F ] , observe document health care provider ) ; Elevated white blood cell count ( &gt; 10,000/mm^3 ) , leave shift ( &gt; 15 % immature PMNs ) ; Nausea vomiting ; Dysuria , increase urinary frequency , urinary urgency ; Flank pain ; Costovertebral angle tenderness physical examination Pyuria evidence 1 following : Positive LCE urinalysis ; White blood cell count ≥10 cells/mm^3 unspun urine ; White blood cell count ≥10 cells/hpf urine sediment 6 . Expectation , judgment Investigator , indwell urinary catheter instrumentation ( include nephrostomy tubes and/or indwell stent ) remove replace ( removal clinically acceptable ) soon possible , longer 12 hour , randomization . 7 . Expectation , judgment Investigator , participant survive effective antibiotic therapy appropriate supportive care anticipate duration study . 8 . Women childbearing potential must negative pregnancy test randomization willing use highly effective method contraception randomization 7 day completion study . A highly effective method contraception include 2 following : hormonal implants/patch , injectable hormone , oral hormonal contraceptive , prior bilateral oophorectomy , prior hysterectomy , prior bilateral tubal ligation , intrauterine device , approve cervical ring , condom , true abstinence ( approved Investigator ) , vasectomized partner . 9 . Willingness comply study procedure , whether hospital discharge , duration study . 1 . Presence follow condition : 1 . Perinephric abscess ; 2 . Renal corticomedullary abscess ; 3 . Uncomplicated UTI ; 4 . Polycystic kidney disease ; 5 . Chronic vesicoureteral reflux ; 6 . Previous plan renal transplantation ; 7 . Participants receive hemodialysis ; 8 . Previous plan cystectomy ileal loop surgery ; 9 . Known candiduria . 2 . Presence suspect confirmed acute bacterial prostatitis , orchitis , epididymitis , chronic bacterial prostatitis determine history and/or physical examination . 3 . Gross hematuria require intervention administration study drug . 4 . Urinary tract surgery within 7 day prior randomization urinary tract surgery plan study period ( except surgery require relieve obstruction place stent nephrostomy ) . 5 . Renal function screen estimate creatinine clearance &lt; 50 mL/minute ( min ) use CockcroftGault formula . 6 . Known nonrenal source infection endocarditis , osteomyelitis , abscess , meningitis , pneumonia diagnose within 7 day prior randomization . 7 . Any following sign severe sepsis : 1 . Shock profound hypotension define systolic blood pressure &lt; 90 millimeter mercury ( mmHg ) decrease &gt; 40 mmHg baseline ( know ) responsive fluid challenge ; 2 . Hypothermia ( temperature &lt; 35.6°C &lt; 96.1°F ) ; 3 . Disseminated intravascular coagulation evidence prothrombin time partial thromboplastin time ≥2 × upper limit normal ( ULN ) platelets &lt; 50 % low limit normal . 8 . Pregnant breastfeed woman . 9 . History epilepsy know seizure disorder require current treatment antiseizure medication . 10 . Treatment within 30 day prior enrollment valproic acid . 11 . Treatment within 30 day prior enrollment probenecid . 12 . Treatment within 30 day prior enrollment cancer chemotherapy , immunosuppressive medication transplantation , medication rejection transplantation . 13 . Evidence significant hepatic disease dysfunction , include know acute viral hepatitis hepatic encephalopathy . 14 . Aspartate aminotransferase alanine aminotransferase &gt; 5 × ULN total bilirubin &gt; 3 × ULN . 15 . Receipt potentially therapeutic antibiotic agent within 48 hour randomization . A pathogencausing cUTI AP resistant prior therapy may enrol study ( assume organism know sensitive piperacillin/tazobactam ) . Participants develop sign symptom cUTI AP antibiotic may also enrol . 16 . Prior exposure vaborbactam alone combination another product . 17 . Receipt potentially therapeutic antibiotic agent within 48 hour randomization . EXCEPTIONS : Participants receive single dose shortacting oral IV antibiotic ( antibiotic typically dosed q4h , q6h , q8h participant normal renal function ) . No 25 % participant enrol meet criterion . Participants receive &gt; 48 hour prior systemic antibiotic therapy current episode cUTI unequivocal clinical evidence treatment failure ( , worsen sign symptom ) . Participants develop sign symptom cUTI AP antibiotic another indication . 18 . Requirement time enrollment reason additional systemic antibiotic therapy ( study drug ) antifungal therapy . Topical antifungal single oral dose antifungal treatment vaginal candidiasis allow . 19 . Likely require use antibiotic cUTI prophylaxis participant 's participation study ( enrollment last follow [ LFU ] visit ) . 20 . Known history human immunodeficiency virus infection know recent CD4 count &lt; 200/mm^3 . 21 . Presence immunodeficiency immunocompromised condition include hematologic malignancy , bone marrow transplant , receive immunosuppressive therapy cancer chemotherapy , medication rejection transplantation , longterm ( ≥2 week ) use systemic corticosteroid . 22 . Presence neutropenia ( &lt; 1,000 PMNs/mm^3 ) . 23 . Presence thrombocytopenia ( &lt; 60,000 platelets/mm^3 ) . 24 . A QTcF &gt; 480 millisecond ( msec ) . 25 . History significant hypersensitivity allergic reaction Carbavance ( meropenem/vaborbactam ) , piperacillin/tazobactam , excipients use respective formulation , betalactam antibiotic ( , cephalosporins , penicillin , carbapenems , monobactams ) . 26 . Known hypersensitivity inability tolerate following : fluoroquinolones ( include levofloxacin ) , trimethoprim/ sulfamethoxazole , cefdinir , cefixime , cefpodoxime , base prescribe information . 27 . Unable unwilling , judgment Investigator , comply protocol . 28 . An employee Investigator study center direct involvement propose study study direction Investigator study center , family member employee Investigator . 29 . Acute Physiology Chronic Health Evaluation ( APACHE ) II score &gt; 30 ( clinically indicate ) 30 . Inability tolerate intravenous fluid , due medical reason , 1050 mL per day require study drug administration . 31 . Any recent history trauma pelvis urinary tract .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>